Idelalisib + Bendamustine, Rituximab: Important New Option for Relapsed/Refractory CLL
Idelalisib in combination with bendamustine and rituximab is superior to bendamustine and rituximab alone.
ASH 2015
Venetoclax for Patients With Ultra-high Risk Relapsed/Refractory CLL
In “ultra-high risk” patients with chronic lymphocytic leukemia (CLL), treatment with venetoclax monotherapy resulted in a high overall response rate.
Phase 3 Trial Supports High-intensity Pretransplant Myeloablative Regimens for MDS, AML
Results of a phase 3 randomized trial support high intensity conditioning prior to allogeneic stem cell transplantation as standard of care.
First-in-Human Trial CAR T Cell Trial Induces Multiple Myeloma Remissions
The first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA) has shown strong anti-myeloma activity.
MRD Complete Response Induced by Blinatumomab Associated With Improved Survival
Minimal residual response (MRD) induced by blinatumomab montherapy was associated with longer survival and duration of response.
Adding Ixazomib to Lenalidomide Plus Dex Improves PFS in Myeloma
Adding ixazomib to lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma increased progression-free survival.
Ibrutinib Improves PFS vs IV Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib is superior to temsirolimus for progression-free survival in patients with relapsed/refractory mantle cell lymphoma (MCL).
Brentuximab Vedotin Plus Bendamustine Active In Heavily Pretreated Hodgkin Lymphoma, ALCL
Combination of brentuximab vedotin with bendamustin is effective in Hodgkin lymphoma and anaplastic large T-cell lymphoma (ALCL).
Obinutuzumab Plus Venetoclax Seems Tolerable in Elderly Patients with CLL, Coexisting Conditions
Obinutuzumab monotherapy for 1 cycle followed by venetoclax and obinutuzumab in elderly patients with chronic lymphocytic leukemia (CLL).
Ibrutinib Monotherapy Superior to Chlorambucil in Treatment-naïve Older Patients With CLL/SLL
brutinib monotherapy was superior to chlorambucil with regard to survival and hematologic improvement.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASH 2015
Loading... 
Loading...